Business
Picard Medical / SynCardia Highlight Total Artificial Heart on BTV Program Airing on FOX Business News
Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programsTUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total Artificial Heart (“STAH”) will be featured in an upcoming segment on BT
About this update from Picard Medical, Inc.
[{"type":"image","alt":"Picard Medical, Inc.","displaySize":"","headline":null,"caption":"Picard Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gcgpu3t6z4ZWVpSIwIEbWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a","width":300,"height":75}},"lazy":false},{"type":"text","content":"Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programs","length":139,"tagName":"p"},{"type":"text","content":"TUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total Artificial Heart (“STAH”) will be featured in an upcoming segment on BTV Business Television airing on the FOX Business News on Saturday, March 14 at 5:00 p.m. EST.","length":454,"tagName":"p"},{"type":"text","content":"The segment will highlight the Company artificial heart technology designed to replace the pumping function of a failing human heart during the time that a patient awaits transplantation.","length":187,"tagName":"p"},{"type":"text","content":"With more than 2,100 implants performed worldwide, the STAH remains the most widely used and extensively studied artificial heart technology globally. The device is considered a “total” replacement since it replaces both left and right ventricles and all four heart valves, restoring circulation in patients with severe biventricular heart failure who are at risk of imminent death without mechanical circulatory support.","length":421,"tagName":"p"},{"type":"text","content":"The segment will also highlight the Company’s development of a next-generation, fully implantable artificial heart platform designed to improve patient mobility and quality of life by eliminating external pneumatic drivers.","length":223,"tagName":"p"},{"type":"text","content":"“We believe raising awareness of advanced heart failure therapies is increasingly important as the number of patients in need of mechani...